Organization
Chinese PLA General Hospital
47 clinical trials
10 abstracts
Abstract
Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors.Org: Department of Bio-therapeutic, Chinese PLA General Hospital, Department of Clinical Research & Development, Shanghai, China, Changzhou, China,
Clinical trial
Using Single-cell Sequencing to Explore Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and ChemotherapyStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase II Clinical Study of Adebrelimab Injection in Combination With Apatinib and Paclitaxel for Injection (Albumin-bound) as Second-line Therapy in Patients With Advanced Gastric Cancer Who Had Previously Received Immunotherapy.Status: Not yet recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase I/II, Open-label, Two-arm, Single-center Study to Evaluate the Safety and Efficacy of the Pan-immunotherapy in Subjects With Relapsed/Refractory Ovarian CancerStatus: Completed, Estimated PCD: 2022-05-22
Clinical trial
Multicenter,Open Label,Phase 2 Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2026-01-31
Clinical trial
Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy: a Multicenter, Randomized, Open-label, Parallel Controlled StudyStatus: Recruiting, Estimated PCD: 2027-05-03
Abstract
Efficacy and safety of surufatinib, toripalimab, nab-paclitaxel in combination with radiotherapy or surgery in the first-line treatment of esophageal squamous cell cancer: A single-centered prospective clinical trial.Org: Chinese PLA General Hospital, Beijing InnoCare Pharma Tech, China National Biotec Group,
Abstract
The interim analysis of a first-in-human phase 1 trial of ET-901, a CRISPR edited allogeneic immune-cloaked anti-CD19 CAR-T cell therapy in patients with r/r B-NHL.Org: Department of Bio-therapeutic, The First Medical Center, Chinese PLA General Hospital, Beijing, China, EdiGene,
Clinical trial
Phase ⅠStudy of GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Treating Patients With Advanced Relapsed or Refractory Hematological Malignancies and Previously Treated Solid TumorsStatus: Completed, Estimated PCD: 2023-11-30
Clinical trial
A Phase 1/2 Single-center Study Evaluating the Safety and Efficacy of TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell (ATHENA-2) Therapy in Adults With Refractory/Relapsed B-cell LymphomaStatus: Recruiting, Estimated PCD: 2026-04-25
Clinical trial
Allogeneic TRAC Locus-inserted CD19-targeting Synthetic T-cell Receptor Antigen Receptor (STAR) T Cells for Relapsed/Refractory B-cell Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2026-03-20
Clinical trial
PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for Patients With RAS-mutant, Microsatellite Stable, Metastatic Colorectal Cancer: a Prospective, Open-label, Single-arm, Phase II TrialStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase I/II Study of Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Effect of Intraoperative Dexmedetomidine on Postoperative Delirium in Elderly Patients Undergoing Major Abdominal Surgery: a Randomized Controlled StudyStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Chinese People's Liberation Army General HospitalStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
A Single-arm, Open Phase II Trial of CAPOX Combined With Bevacizumab Combined With Tirelizumab in First-line Treatment of PDL1 CPS < 5 Advanced Gastroesophageal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Safety and Efficacy Evaluation of S (+) -Ketamine for Postoperative Acute Pain in Children in Perioperative Settings: A Multicenter, Randomized, Open-label, Active Controlled Pragmatic Clinical TrialStatus: , Estimated PCD: 2024-12-01
Clinical trial
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer: a Prospective, Randomized Controlled Clinical TrialStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Effect of Intraoperative Use of Dexmedetomidine on Postoperative Mental Disorders and Long-term Survival in Elderly Patients Undergoing Non-cardiac SurgeryStatus: Completed, Estimated PCD: 2023-05-25
Clinical trial
Ruxolitinib in Combination With Corticosteroid as First Line Therapy for the Treatment of High Risk Acute Graft-Versus-Host DiseaseStatus: Completed, Estimated PCD: 2022-08-01
Clinical trial
First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With MalignantStatus: Completed, Estimated PCD: 2023-11-30
Clinical trial
Phase I/II Clinical Trial of HER2 Targeted HypoSti.CAR-T Cells in Treating Patients With HER2 Positive Local Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Multiple Center Study on NOXA Expression-guided Randomized Chidamide Bridging Intervention in CAR-T Treated NHL PatientsStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Prospective,Randomized,and Comparative Study on the Efficacy of Venetoclax Combined With CACAG Regimen and BAT Regimen in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2026-01-31
Clinical trial
A Phase 1/2 Single-center Study Evaluating the Safety and Efficacy of TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell (ATHENA) Therapy in Adults With Refractory/Relapsed B-cell Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Pilot Clinical Trial of Autologous EphA-2-Targeting Chimeric Antigen Receptor Dendritic Cell Vaccine Loaded With KRAS Mutant Peptide in Combination With Anti-PD-1 Antibody/Anti-CTLA4 Antibody for Local Advanced/Metastatic Solid Tumors.Status: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Pilot Clinical Trial of Autologous EphA-2-Targeting Chimeric Antigen Receptor Dendritic Cell Vaccine Loaded With TP53 Mutant Peptide Plus ICIs for Local Advanced/Metastatic Solid Tumors or Relapsed/Refractory Lymphomas.Status: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
Allogenic CD19-targeting Chimeric Antigen Receptor γδT Cells Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Efficiency and Safety of Paxlovid for the Treatment of COVID-19 Patients With Severe Chronic Kidney DiseaseStatus: Recruiting, Estimated PCD: 2025-05-30
Clinical trial
Autologous TRAC Locus-inserted CD19-targeting Synthetic T-cell Receptor Antigen Receptor T (STAR-T) Cells for Relapsed/Refractory B-cell Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
An Open-Label Phase Ⅰ/Ⅱ Study of EZH2 Inhibitor SHR2554 in Combination With Anti-PD-L1/TGFβ Antibody SHR1701 in Patients With Advanced or Metastatic Solid Tumors and Relapsed/Refractory B-cell LymphomasStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Prospective, Single-arm, Single-center Phase Ib/II Trial on the Safety and Efficacy of Fruquintinib in Combination With FOLFIRI in RAS-mutated Metastatic Colorectal CancerStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Open Label，Single Arm，Phase Ib/II Study to Evaluate the Effect and Safety of RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Phase I/II Study of CD70 Targeted CAR-T Cell Treatment in CD70 Positive Advanced/Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Multicenter, Open Label, Single-arm Exploratory Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV InfectionStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Multicenter, Open Label, Single-arm Exploratory Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCTStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Phase I/II Study of CD70 Targeted CAR-T Cell Treatment in CD70 Positive Relapsed/Refractory LymphomaStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
An Open-Label Phase I/II Study of SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Impact of Optimal Doses of Antithymocyte Globulin Conditioning on Graft-versus- Host Disease and Virus Reactivation in Haploidentical Hematopoietic Stem Cell TransplantationStatus: Active (not recruiting), Estimated PCD: 2022-07-31
Clinical trial
Phase I/II Trial of Allograft Engineered MSC-IFNα Combined With or Without Immunochemotherapy for Locally Advanced/Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Randomized, Open-label, Phase 2 Trial of Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma.Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma：a Single-center, Open-label, Phase II Clinical Trial.（REPLY Study）Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Chinese Real-world Study of Rimegepant for the Acute Treatment of MigraineStatus: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
Low-Dose Decitabine Plus Anti-PD-1 Treatment for Relapsed/Refractory Diffuse Large B Cell Lymphoma With Extranodal (Esp. Central Nervous System) Involvement: A PhaseⅡClinical TrialStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell LymphomaStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Adoptive Immunotherapy With Donor-derived CMV-TCR-T Cells for Patients With CMV Infection After Allogenic HSCTStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Volatile Anaesthetics on Incidence of Postoperative Depression and AnxietyStatus: Completed, Estimated PCD: 2021-10-31
Abstract
Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases.Org: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China, Department II of breast, Linyi Cancer Hospital,
Abstract
Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases.Org: The First Medical Center of PLA General Hospital, Chinese PLA General Hospital, Fifth Medical Center of Chinese PLA General Hospital, 5th Medical Center of the PLA General Hospital,
Abstract
Donafenib combined with anti-PD-1 antibody as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: A retrospective analysis.Org: Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Institute of Hepatobiliary Surgery of Chinese PLA, Key Laboratory of Digital Hepetobi, the 301th Hospital of Chinese PLA,
Abstract
Construction of a prognostic hierarchical model for patients with HER2 positive breast cancer with brain metastases.Org: The Fifth Medical Centre of Chinese PLA General Hospital, Chinese PLA General Hospital, Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, Fujian Medical University Union Hospital,
Abstract
A phase 2 study of modified chemotherapy plus pembrolizumab as perioperative therapy for stage II/IIIA esophageal squamous cell carcinoma.Org: The First Medical Center of PLA General Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, General Hospital of Chinese PLA, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Chinese PLA General Hospital,
Abstract
Multi-omics analysis to reveal the change of peripheral blood TCR repertoire and tumor burden during neoadjuvant chemotherapy combined with sequential PD-1 blockade for patients with non-small cell lung cancers: A single-center, single-arm phase 2 trial.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Chinese PLA General Hospital, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, School of Medicine Nankai University,
Abstract
A RETROSPECTIVE STUDY OF ARTHROSCOPIC SYNOVECTOMY FOR REFRACTORY KNEE ARTHRITIS COMPLICATED WITH POPLITEAL CYSTOrg: Chinese PLA General Hospital, Department of Rheumatology, Beijing, China,
Clinical trial
Safety and Efficacy of Zanubrutinib in Combination With Rituximab and Venetoclax in Previously Untreated Follicular Lymphoma: An Open Label, Phase 2 StudyStatus: Recruiting, Estimated PCD: 2026-12-30
Clinical trial
A Phase 1/2 Single-center Study Evaluating the Safety and Efficacy of TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in Adults With Refractory/Relapsed B-cell Acute Lymphoblastic LeukaemiaStatus: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Transfusion for the Treatment of Refractory Lupus NephritisStatus: Not yet recruiting, Estimated PCD: 2026-10-01